Objective response at week 25 was 54% with pimicotinib versus 3% with placebo, supporting robust antitumor activity in unresectable TGCT. Patient-reported endpoints showed meaningful improvements in ...
Emactuzumab has received FDA fast track designation for TGCT treatment, aiding development for conditions lacking effective options. The phase 3 TANGENT trial evaluates emactuzumab, a CSF-1R ...
Results from a phase 1 trial showed the independently reviewed best overall objective response rate was 71% in emactuzumab-treated patients. The Food and Drug Administration (FDA) has granted Fast ...
Neo-adjuvant radiation and intratumoral immunotherapy followed by surgery: The NARIS trial for extremity soft tissue sarcoma. Longer-term PROMIS-PF scores per item from baseline to week 49.
At its July 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization in the European Union for Romvimza ...
DelveInsight's Tenosynovial Giant Cell Tumors Market Insights report includes a comprehensive understanding of current treatment practices, emerging tenosynovial giant cell tumors drugs, market share ...
Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors. At a median follow-up of 14.3 months, the ORR had ...
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application ...
BOSTON--(BUSINESS WIRE)--EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results